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Introduction
Efficacy and safety of TCZ, an IL-6 receptor inhibitor,
were previously demonstrated at wk 40 of CHERISH,
a phase 3 trial in patients (pts) with pcJIA [1].
Objectives
To investigate efficacy and safety of TCZ over 104 wks of
treatment in pcJIA.
Methods
Pts 2-17 years old with ≥6 months’ active pcJIA who
failed methotrexate received open-label (OL) TCZ
(weight ≥30 kg, 8 mg/kg [n = 119]; weight <30 kg, rando-
mised [1:1] to 8 [n = 34] or 10 [n = 35] mg/kg) every
4 wks for 16 wks. Pts with ≥JIA ACR30 response at wk
16 entered a 24-wk double-blind withdrawal period and
were randomised (1:1) to placebo or continuation with
TCZ. Pts with JIA ACR30 flare or who completed the
withdrawal period entered an OL extension through
wk 104.
Results
188 pts entered the lead-in period, 166 entered the
withdrawal period, 160 entered the OL extension period
and 155 completed 104 wks. In pts who received TCZ
throughout the study, JIA ACR responses and improve-
ment in JIA ACR core components (Table) were main-
tained through wk 104. The safety population comprised
188 pts with 307 pt years (PY). Rates/100PY of AEs and
serious AEs (SAEs) were 406.5 and 11.1, respectively;
infections were the most common AE (151.4) and SAE
(5.2). ALT and AST elevations ≥3 × upper limit of normal
occurred in 6.4% and 2.7% of pts, respectively. Grade 3
neutropenia and grade 2/3/4 thrombocytopenia occurred
in 5.9% and 1.6% of pts, respectively. LDL cholesterol
≥110 mg/dl occurred in 16.2% of pts.
Conclusion
Efficacy of TCZ was maintained through 2 years of
treatment in pts with pcJIA, with no change in safety
profile from that reported previously [1].
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Table 1 JIA ACR50/70 responses and percentage change
from baseline in components,a mean ± SD
All TCZ (N = 82)
Wk 40 Wk 104
JIA ACR70 responders,a n (%) 65 (79.3) 71 (86.6
JIA ACR90 responders,a n (%) 41 (50.0) 58 (70.7)
Active joints (0-71) -82.4 ± 24.9 -87.7 ± 27.1
Joints with limitation in ROM (0-67) -73.5 ± 30.7 81.3 ± 31.7
Patient globalc (VAS 0-100 mm) -62.5 ± 76.3 -75.4 ± 43.8
Physician global (VAS 0-100 mm) -85.3 ± 16.8 -89.7 ± 23.7
CHAQ-DI (0-3) -66.0 ± 44.7 -76.7 ± 34.7
ESR (mm/h) -76.5 ± 22.0 -76.2 ± 27.3
aPts who withdrew are excluded. bPts who withdrew due to non-safety
reasons are non-responders. Pts who withdrew due to safety are included
using last observation carried forward. cParent-rated.
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